Using genetics to understand the role of kidney function in COVID-19: a mendelian randomization study

Abstract Background Kidney dysfunction occurs in severe COVID-19, and is a predictor of COVID-19 mortality. Whether kidney dysfunction causes severe COVID-19, and hence is a target of intervention, or whether it is a symptom, is unclear because conventional observational studies are open to confound...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Jie V. Zhao, C. Mary Schooling
Formato: article
Lenguaje:EN
Publicado: BMC 2021
Materias:
Acceso en línea:https://doaj.org/article/3c669e3ede624482ad9dd9feade77c76
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:3c669e3ede624482ad9dd9feade77c76
record_format dspace
spelling oai:doaj.org-article:3c669e3ede624482ad9dd9feade77c762021-11-14T12:43:55ZUsing genetics to understand the role of kidney function in COVID-19: a mendelian randomization study10.1186/s12882-021-02586-61471-2369https://doaj.org/article/3c669e3ede624482ad9dd9feade77c762021-11-01T00:00:00Zhttps://doi.org/10.1186/s12882-021-02586-6https://doaj.org/toc/1471-2369Abstract Background Kidney dysfunction occurs in severe COVID-19, and is a predictor of COVID-19 mortality. Whether kidney dysfunction causes severe COVID-19, and hence is a target of intervention, or whether it is a symptom, is unclear because conventional observational studies are open to confounding. To obtain unconfounded estimates, we used Mendelian randomization to examine the role of kidney function in severe COVID-19. Methods We used genome-wide significant, uncorrelated genetic variants to predict kidney function, in terms of estimated glomerular filtration rate (eGFR) and urine albumin-to-creatinine ratio (UACR), and then assessed whether people with genetically instrumented higher eGFR or lower UACR, an indication of better kidney function, had a lower risk of severe COVID-19 (8779 cases, 1,001,875 controls), using the largest available cohorts with extensive genotyping. For comprehensiveness, we also examined their role in COVID-19 hospitalization (24,274 cases, 2,061,529 controls) and all COVID-19 (1,12,612 cases, 2,474,079 controls). Results Genetically instrumented higher eGFR was associated with lower risk of severe COVID-19 (odds ratio (OR) 0.90, 95% confidence interval (CI) 0.83, 0.98) but not related to COVID-19 hospitalization or infection. Genetically instrumented UACR was not related to COVID-19. Conclusions Kidney function appears to be one of the key targets for severe COVID-19 treatment. Use of available medications to improve kidney function, such as antihypertensives, might be beneficial for COVID-19 treatment, with relevance to drug repositioning.Jie V. ZhaoC. Mary SchoolingBMCarticleDiseases of the genitourinary system. UrologyRC870-923ENBMC Nephrology, Vol 22, Iss 1, Pp 1-6 (2021)
institution DOAJ
collection DOAJ
language EN
topic Diseases of the genitourinary system. Urology
RC870-923
spellingShingle Diseases of the genitourinary system. Urology
RC870-923
Jie V. Zhao
C. Mary Schooling
Using genetics to understand the role of kidney function in COVID-19: a mendelian randomization study
description Abstract Background Kidney dysfunction occurs in severe COVID-19, and is a predictor of COVID-19 mortality. Whether kidney dysfunction causes severe COVID-19, and hence is a target of intervention, or whether it is a symptom, is unclear because conventional observational studies are open to confounding. To obtain unconfounded estimates, we used Mendelian randomization to examine the role of kidney function in severe COVID-19. Methods We used genome-wide significant, uncorrelated genetic variants to predict kidney function, in terms of estimated glomerular filtration rate (eGFR) and urine albumin-to-creatinine ratio (UACR), and then assessed whether people with genetically instrumented higher eGFR or lower UACR, an indication of better kidney function, had a lower risk of severe COVID-19 (8779 cases, 1,001,875 controls), using the largest available cohorts with extensive genotyping. For comprehensiveness, we also examined their role in COVID-19 hospitalization (24,274 cases, 2,061,529 controls) and all COVID-19 (1,12,612 cases, 2,474,079 controls). Results Genetically instrumented higher eGFR was associated with lower risk of severe COVID-19 (odds ratio (OR) 0.90, 95% confidence interval (CI) 0.83, 0.98) but not related to COVID-19 hospitalization or infection. Genetically instrumented UACR was not related to COVID-19. Conclusions Kidney function appears to be one of the key targets for severe COVID-19 treatment. Use of available medications to improve kidney function, such as antihypertensives, might be beneficial for COVID-19 treatment, with relevance to drug repositioning.
format article
author Jie V. Zhao
C. Mary Schooling
author_facet Jie V. Zhao
C. Mary Schooling
author_sort Jie V. Zhao
title Using genetics to understand the role of kidney function in COVID-19: a mendelian randomization study
title_short Using genetics to understand the role of kidney function in COVID-19: a mendelian randomization study
title_full Using genetics to understand the role of kidney function in COVID-19: a mendelian randomization study
title_fullStr Using genetics to understand the role of kidney function in COVID-19: a mendelian randomization study
title_full_unstemmed Using genetics to understand the role of kidney function in COVID-19: a mendelian randomization study
title_sort using genetics to understand the role of kidney function in covid-19: a mendelian randomization study
publisher BMC
publishDate 2021
url https://doaj.org/article/3c669e3ede624482ad9dd9feade77c76
work_keys_str_mv AT jievzhao usinggeneticstounderstandtheroleofkidneyfunctionincovid19amendelianrandomizationstudy
AT cmaryschooling usinggeneticstounderstandtheroleofkidneyfunctionincovid19amendelianrandomizationstudy
_version_ 1718429041468375040